RxDoctor Payments Data

Viktor Gribenko, MD

Physical Medicine & Rehabilitation · Brooklyn, NYNPI 1659471944

Payments from drug & device makers

$6,035in general payments, 2019–2025

Across 95 payments — averaging $63.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$609
  • Pfizer$583
  • Indivior Inc.$491
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$491
  • Orexo US, Inc.$196
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$6,035100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,035 in reported general payments places this provider in the 90th percentile of 872 physical medicine & rehabilitation providers in New York.

See all physical medicine & rehabilitation providers in New York

Medicare billing

Part B allowed, 2024
$70,422
Medicare patients
46
Services billed
1,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl201$28,871
UbrelvyUbrogepant13$26,021
ZubsolvBuprenorphine Hcl/Naloxone Hcl26$3,919
Incruse ElliptaUmeclidinium Bromide11$3,830
Diclofenac Sodium28$3,030
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen77$1,797
Oxycodone Hcl77$902
Albuterol Sulfate HfaAlbuterol Sulfate29$608
Gabapentin91$424
Acetaminophen-CodeineAcetaminophen With Codeine11$402
Alprazolam134$401
Valsartan27$293
Quetiapine Fumarate27$249
Tramadol Hcl31$185
Olanzapine27$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$2,433$26,02113 claims
Orexo US, Inc.Zubsolv$196$3,91926 claims
GSKIncruse Ellipta$609$3,83011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 872 physical medicine & rehabilitation providers in New York.

Other physical medicine & rehabilitation in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →